RARE Ultragenyx Pharmaceutical Inc.

58.52
-1.49  -2%
Previous Close 60.01
Open 60.27
Price To book 5.19
Market Cap 2.48B
Shares 42,312,000
Volume 313,639
Short Ratio 10.96
Av. Daily Volume 578,362

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released July 2016. Primary endpoint hit. Secondary missed. PDUFA date under priority review November 16, 2017.
rhGUS
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 to be initiated 1H 2017.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data due 2H 2017.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Phase 3 data released April 18, 2017 - primary endpoint met. BLA fiing due 2H 2017.
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH) - adult
Interim data released April 2016. Additional data released September 2016.
KRN23 Burosumab
Tumor-induced osteomalacia (TIO)
Phase 3 enrollment commenced October 2016.
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH) - pediatric
Phase 2 initiated March 2014. Data released March 22, 2017 - primary endpoint not met. Phase 3 trial initiation announced April 27, 2017.
UX007 (triheptanoin)
Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)
Phase 2 interim data released October 2015. 78-week data released November 30, 2016. Phase 3 planned for 2017.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)

Latest News

  1. Ultragenyx Receives Priority Review for rhGUS from FDA
  2. Ultragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
  3. Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc.
  4. Edited Transcript of RARE earnings conference call or presentation 4-May-17 9:00pm GMT
  5. Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
  6. Ultragenyx reports 1Q loss
  7. Ultragenyx Reports First Quarter 2017 Financial Results and Corporate Update
  8. What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?
  9. Ultragenyx to Host Conference Call for First Quarter 2017 Financial Results and Corporate Update
  10. Ultragenyx Initiates Global Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement Disorders
  11. What's in Store for Nivalis (NVLS) this Earnings Season?
  12. Company News for April 20, 2017
  13. Energy, biotech, financials & more in the trader blitz
  14. Analyst Sees Ultragenyx Shares Range Bound Despite Positive Data
  15. Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III
  16. Why Ultragenyx Pharmaceutical Stock Is Spiking Today
  17. The Next Steps For Ultragenyx' Burosumab Following Positive Phase 3 Data
  18. Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data
  19. Ultragenyx surges on positive results for hypophosphatemia drug test
  20. After-hours buzz: IBM, LRCX, RARE & more